While at the National Institutes of Health, Dr. Demidowich was very active in research, particularly in the areas of obesity and endocrine hypertension. He was the Principal Investigator of two protocols and Lead-associate Investigator of two others.
With Dr. Jack Yanovski, he created a randomized, placebo controlled pilot study investigating the use of colchicine to ameliorate obesity-induced inflammation and improve metabolic markers of health. The study completed in July 2018, and the results are in process of being published.
Additionally, under Dr. Constantine Stratakis, Dr. Demidowich studied various clinical aspects of Primary Aldosteronism, including the genetic underpinnings of aldosterone-producing adenomas.
View all on Pubmed
Hannah-Shmouni F, Demidowich A, Alves BR,Paluch GD, Lysikatos C, Belyavskaya E, Chang R, Stratakis CA. Management of primary aldosteronism in patients with adrenal hemorrhage following adrenal vein sampling: A brief review with illustrative cases. J Clin Hypertens (Greenwich). 2017 Dec;19(12):1372-1376.
Demidowich A, Jun JY, Yanovski JA. Polymorphisms and mutations in the melanocortin-3 receptor and their relation to human obesity. Biochim Biophys Acta. 2017 Oct;1863(10 Pt A):2468-2476.
Hannah-Shmouni F, Demidowich A, Stratakis C. Cortisol in the Evaluation of Adrenal Insufficiency. JAMA. 2016;316(5):535.
Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Medical Hypotheses. 2016 Jul;92:67-73.
Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schäffer AA, Puck JM, Grimbacher B. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007 Oct 18; 357(16):1608-19.